DVAX Price Prediction Next Week
Analysis and Insights
News and Event Impact:
Insider Selling Activity: David F. Novack, President & COO of DVAX, sold 32,764 shares, representing 59.7% of his holdings, leaving him with 22,098 shares. This significant insider selling may signal reduced confidence in the company's short-term prospects.
Institutional Investor Movements: While 132 institutional investors increased their positions, 133 reduced theirs, indicating mixed sentiment among large shareholders.
Options Trading Insights: The put contract at $13.00 has a 73% chance of expiring worthless, suggesting market participants expect the stock to remain above this level. The call contract at $14.00 has a 45% chance of expiring worthless, indicating moderate bullish sentiment.
FDA Approval Impact: Although not directly related to DVAX, the FDA approval of Alnylam's Amvuttra highlights positive momentum in the biotech sector, which could indirectly support DVAX.
Technical Analysis:
Current Price: DVAX is trading at $13.85 as of the latest data.
Fibonacci Levels: The stock is currently trading near the pivot point of $13.87, with resistance at $14.22 and support at $13.51.
RSI and MACD: The RSI is at 54, indicating a neutral position, while the MACD is slightly positive, suggesting mild upward momentum.
Price Action: The stock has been consolidating near the $14.00 level, with recent highs at $14.07 and lows at $13.75.
Price Forecast and Recommendation:
Based on the analysis, DVAX is expected to trade in a narrow range with a slight upward bias. The stock is likely to test the resistance at $14.10, with support at $13.75.
Prediction: The stock price of DVAX is expected to reach $14.10 by the end of the next trading week.
Recommendation: Buy at the current price level, with a target of $14.10 and a stop-loss at $13.50.
DVAX Similar Chart Price Prediction
The price of DVAX is predicted to go up 13.05%, based on the high correlation periods with GLBE. The similarity of these two price pattern on the periods is 96.14%.
DVAX
GLBE
Up: 13.05%Similarity: 96.14%
DVAX Revenue Forecast
DVAX EPS Forecast
DVAX FAQs
What is DVAX revenue forecast for next quarter？
DVAX Analyst's Forecast
Jason Butler
Citizens Capital Markets
Buy
2025-02-21
Price Target
$29 → $33
Upside
+147.56%
Citizens JMP raised the firm's price target on Dynavax to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported fiscal 2024 results in line with January's preannouncement, and management remains optimistic on the potential for bringing in value-add, late-stage assets in the infectious disease space as the best way to maximize the value of its hepatitis B vaccine, HEPLISAV-B, the analyst tells investors in a research note. Management also continues to seek out assets in the infectious disease space, and believes there are viable assets, the firm notes.
Paul Choi
Goldman Sachs
Hold → Strong Sell
2025-02-11
Price Target
$15 → $12
Downside
-5.51%
